Printer Friendly

PRIME MEDICAL SERVICES AND HARRIS CLINICAL DEVELOPMENT JOIN FORCES TO STRENGTHEN CARDIOVASCULAR DRUG RESEARCH

PRIME MEDICAL SERVICES AND HARRIS CLINICAL DEVELOPMENT JOIN FORCES TO
 STRENGTHEN CARDIOVASCULAR DRUG RESEARCH
 AUSTIN, Texas, Nov. 20 /PRNewswire/ -- Prime Medical Services, Inc. (NASDAQ: PMSI), the nation's leading provider of cardiac rehabilitation programs, announced that it has joined forces with Harris Clinical Development to offer cardiovascular drug research trials to pharmaceutical manufacturers.
 This partnership offers a unique opportunity to the pharmaceutical industry. It provides a network of centers throughout all regions of the United States, including hundreds of experienced internists and cardiologists involved in the care and management of patients with cardiovascular diseases, coupled with a long and highly regarded track record of providing accurate and efficient drug trial test results. The partnership has the ability to conduct studies for the pharmaceutical industry, which is estimated to have spent over 13 billion dollars last year on clinical drug studies, in many areas including hypertension, lipid reduction, angina, congestive heart failure, ischemic heart disease and peripheral vascular disease.
 Jackie Majors, president of Prime, stated, "Prime offers a comprehensive monitored, multi-disciplined program of cardiovascular rehabilitation. Not only does Prime bring experienced physicians and an extensive patient base to the table, we also have more than 100 trained nurses in coronary care and a large pool of administrative personnel experienced in the documentation and administration of cardiac patients. Each of the facilities provides comprehensive cardiac testing capabilities."
 Headquartered in Scottsdale, Ariz., Harris supports clinical projects with study design consultation, computerized trial management reporting, a central internal review board, a central laboratory and complete statistical analysis services. With nearly 60 years experience, Harris has earned a strong reputation in the industry for providing accurate and efficient results.
 Majors announced that Prime has signed a contract with Pfizer, Inc. for a cardiovascular clinical research project. Majors stated, "This project involves a promising new agent, Amlodipine, for the treatment of patients with congestive heart failure." The study will be conducted in several of Prime's cardiac facilities and will research the effects of Amlodipine on exercise tolerance and safety in patients with chronic symptomatic heart failure.
 Majors added, "A previously announced clinical research study that Prime engaged in has been ended due to a change in the business relationship between the two pharmaceutical companies who were sponsoring the study."
 Prime is currently offering its services to other pharmaceutical companies for additional clinical research studies which will be placed within the network of Prime's cardiac centers throughout the country. Majors added, "The new partnership of Prime and Harris offers significant opportunities in the exciting and growing area of clinical drug studies."
 -0- 11/20/91
 /CONTACT: Jackie Majors, president, or Cheryl McLeod, vice president-finance of Prime Medical Services, 512-328-2892/
 (PMSI) CO: Prime Medical Services Inc. ST: Illinois IN: HEA SU: SH -- NY032 -- 5360 11/20/91 11:03 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 20, 1991
Words:461
Previous Article:GTE AND AT&T ANNOUNCE MAJOR, STRATEGIC CELLULAR-SERVICE AGREEMENT; MAKING CELLULAR SHOPPING EASIER
Next Article:MASADA INDUSTRIAL SERVICES IN CONJUNCTION WITH O'BRIEN & GERE ACQUIRES FOURTH COAST POLLUTION CONTROL


Related Articles
HECTOR J. GOMEZ, M.D., PH.D., JOINS VERTEX AS VP MEDICAL AFFAIRS
Speedel Appoints Medical Director With Broad Experience.
Ross Tonkens, MD.
Arginox Appoints David R. Hathaway, M.D. as Chief Medical Officer.
Clinsys Clinical Research, Inc. Announces Key Hire, Hartmut Schmied, MD, to Strengthen European Service Offering and Global Cardiovascular...
Clinsys Clinical Research, Inc. Announces Key Hire, Hartmut Schmied, MD, to Strengthen European Service Offering and Global Cardiovascular...
Expert Cardiologist Joins Quintiles Medical Group.
RPS Enhances Clinical Expertise and Leadership with Two Additions to Senior Management Team.
RPS Enhances Clinical Expertise and Leadership with Two Additions to Senior Management Team.
MDS Pharma Services Strengthens Medical Leadership in Phase IIa Clinical Research.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters